Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - NatureGDF-15 targeting may improve cancer treatment efficacy alongside existing anti-PD-1 therapies.Clinical trials indicate the potential of visugromab in overcoming immune escape mechanisms in tumours.